Hypercoagulability is independently associated with kynurenine pathway activation in dialysed uraemic patients

Krystyna Pawlak; Michal Mysliwiec; Dariusz Pawlak

doi:10.1160/TH08-10-0696

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2009; 102(01): 49-55
DOI: 10.1160/TH08-10-0696

Blood Coagulation, Fibrinolysis and Cellular Haemostasis

Schattauer GmbH

Hypercoagulability is independently associated with kynurenine pathway activation in dialysed uraemic patients

Krystyna Pawlak

¹Department of Monitored Pharmacotherapy, Medical University, Bialystok, Poland

,

Michal Mysliwiec

²Department of Nephrology and Clinical Transplantation, Medical University, Bialystok, Poland

,

Dariusz Pawlak

¹Department of Monitored Pharmacotherapy, Medical University, Bialystok, Poland

³Department of Medical Science, University of Warmia and Mazury, Olsztyn, Poland

› Author Affiliations

Abstract

Summary

Patients with end-stage renal disease (ESRD) exhibit features of a hypercoagulable state, which may contribute to atherosclerosis. Kynurenines are the metabolites of tryptophan degradation in mammals. We examined the relationship between coagulation activation and kynurenines in 92 patients with ESRD on maintenance haemodialysis (HD) or continuous ambulatory peritoneal dialysis (CAPD) and 20 healthy controls. We measured the plasma levels of: tissue factor (TF), its pathway inhibitor (TFPI), the marker of coagulation activation – prothrombin fragments 1+2 (F₁₊₂), kynurenine (KYN) and its metabolites: kynurenic (KYNA), anthranilic (AA) and quinolinic (QA) acids. The ratio of KYNA to KYN (kyna/kyn), AA to KYN (aa/kyn) and QA to KYN (qa/kyn), reflecting intensified activity of enzymes which converted KYN to its metabolites, were also determined. Measured coagulation parameters and kynurenines were significantly elevated in ESRD patients compared to controls. TF, TFPI and F₁₊₂ were significantly associated with AA, aa/kyn, QA and qa/kyn ratio. Multiple regression analysis showed that fibrinogen (p<0.01) and above mentioned KYN metabolites (all p<0.05) were the independent variables significantly associated with increased F₁₊₂ levels, reflecting hypercoagulability in ESRD patients. In conclusion, this study represents the first to investigate both the coagulation system and KYN pathway in ESRD patients. The coagulation was enhanced in dialysed uraemic patients compared with the healthy controls demonstrated by increased TF, TFPI and F₁₊₂ levels. These changes were correlated with activation of the KYN pathway. Finally, fibrinogen and KYN metabolites are independently and significantly associated with the hypercoagulable state in uraemic patients on CAPD and HD treatment.

Keywords

Blood coagulation - end-stage renal disease (ESRD) - hypercoagulability - kynurenines - tissue factor - tissue factor pathway inhibitor

Full Text

References

References
1 Prichard S. Cardiovascular risk in peritoneal dialysis. Contrib Nephrol 2003; 140: 82-90.
2 Lameire N, Bernaert P, Lambert M-C. et al. Cardiovascular risk factors and their management in patients on continuous ambulatory peritoneal dialysis. Kidney Int 1994; 46 (Suppl. 48) S31-S38.
3 Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 1998; 32 (Suppl. 03) S112-S119.
4 Sarnak MJ, Levey AS. Cardiovascular disease and chronic renal disease: a new paradigm. Am J Kidney Dis 2000; 35 (Suppl. 01) S117-S131.
5 Viener A, Aviram M, Better OS. et al. Enhanced in vitro platelet aggregation in hemodialysis patients. Nephron 1986; 43: 139-143.
6 Toulon P, Jacquot C, Capron L. et al. Antithrombin III and heparin cofactor II in patients with chronic renal failure undergoing hemodialysis. Thromb Haemost 1987; 57: 263-268.
7 Malyszko J, Malyszko JS, Mysliwiec M. Comparison of hemostasis between CAPD and HD patients. Perit Dial Int 2001; 21: 158-165.
8 Kobayashi M, Yorioka N, Yamakido M. Hypercoagulability and secondary hyperfibrinolysis may be related to abnormal lipid metabolism in patients treated with continuous ambulatory peritoneal dialysis. Nephron 1997; 76: 56-61.
9 Vaziri ND, Shah GM, Winer RL. et al. Coagulation cascade, fibrinolytic system, antithrombin III, protein C and protein S in patients maintained on continuous ambulatory peritoneal dialysis. Thromb Res 1989; 53: 173-180.
10 Wiiger MT, Prydz H. The changing faces of tissue factor biology – a personal tribute to the understanding of the “extrinsic coagulation activation”. Thromb Haemost 2007; 98: 38-42.
11 Engelmann B, Luther T, Müller I. Intravascular tissue factor pathway – a model for rapid initiation of coagulation within the blood vessel. Thromb Haemost 2003; 89: 3-8.
12 Farred J, Hoppensteadt DA, Leya F. et al. Thrombogenesis in myocardial infartion and related syndromes: the role of molecular markers in diagnosis and management. Clin Appl Thromb/Haemost 1999; 05: 78-91.
13 Kaikita K, Takeya M, Ogawa H. et al. Co-localization of tissue factor and tissue factor pathway inhibitor in coronary atherosclerosis. J Pathol 1999; 188: 180-188.
14 Pawlak K, Borawski J, Naumnik B. et al. Relationship between oxidative stress and extrinsic coagulation pathway in haemodialyzed patients. Thromb Res 2003; 109: 247-251.
15 Pawlak K, Naumnik B, Brzosko S. et al. Oxidative stress- a link between endothelial injury, coagulation activation, and atherosclerosis in haemodialysis patients. Am J Nephrol 2004; 24: 154-161.
16 Pawlak K, Pawlak D, Mysliwiec M. Association between tissue factor, its pathway inhibitor and oxidative stress in peritoneal dialysis patients. Blood Coagul Fibrinolysis 2007; 18: 467-471.
17 Zemanova P, Opatrny Jr K, Opatrna S. et al. Tissue factor, its pathway inhibitor, and metabolic disturbances in long-term peritoneal dialysis. Kidney Blood Press Res 2003; 26: 368-375.
18 Sagripanti A, Cozza V, Baicchi U. et al. Increased thrombin generation in patients with chronic renal failure. Int J Clin Lab Res 1997; 27: 72-75.
19 Kario M, Matsuo T, Yamada T. et al. Factor VII hyperactivity in chronic dialysis patients. Thromb Res 1992; 67: 105-109.
20 Stone TW. Neuropharmacology of quinolinic and kynurenic acids. Pharmacol Rev 1993; 45: 309-379.
21 Schwarcz R. The kynurenine pathway of tryptophan degradation as a drug target. Curr Opin Pharmacol 2004; 04: 12-17.
22 Pawlak D, Tankiewicz A, Matys T. et al. Peripheral distribution of kynurenine metabolites and activity of kynurenine pathway enzymes in renal failure. J Physiol Pharmacol 2003; 54: 175-189.
23 Pawlak D, Tankiewicz A, Buczko W. Kynurenine and its metabolites in the rat with experimental renal insufficiency. J Physiol Pharmacol 2001; 52: 755-766.
24 Pawlak D, Pawlak K, Malyszko J. et al. Accumulation of toxic products degradation of kynurenine in hemodialyzed patients. Int Urol Nephrol 2001; 33: 399-404.
25 Pawlak K, Domaniewski T, Mysliwiec M. et al. The kynurenines are associated with oxidative stress, inflammation and the prevalence of cardiovascular disease in patients with end-stage renal disease. Atherosclerosis 2009; 204: 309-314.
26 Pawlak K, Brzosko S, Mysliwiec M. et al. Kynurenine, quinolinic acid – the new factors linked to carotid atherosclerosis in patients with end-stage renal disease. Atherosclerosis 2009; 204: 561-566.
27 Schroecksnadel K, Frick B, Winkler C. et al. Crucial role of interferon-γ and stimulated macrophages in cardiovascular disease. Curr Vasc Pharmacol 2006; 04: 205-213.
28 Baldo-Enzi G, Baiocchi MR, Bertazzo A. et al. Tryptophan and atherosclerosis. Adv Exp Med Biol 1996; 398: 429-432.
29 Rudzite V, Sileniece G, Liepina D. et al. Impairment of kynurenine metabolism in cardiovascular disease. Adv Exp Med Biol 1991; 294: 663-667.
30 Wirleitner B, Rudzite V, Neurauter G. et al. Immune activation and degradation of tryptophan in coronary heart disease. Eur J Clin Invest 2003; 33: 550-554.
31 Koenig W, Ernst E. Fibrinogen and atherothrombogenesis. Curr Opin Lipidol 1993; 04: 471-476.
32 Irish A. Cardiovascular disease, fibrinogen and the acute phase response. Associations with lipids and blood pressure in patients with chronic renal disease. Atherosclerosis 1998; 137: 133-139.
33 Brisseau GF, Dackiw APB, Cheung PYC. et al. Posttranscriptional regulation of macrophage tissue factor expression by antioxidants. Blood 1995; 85: 1025-1035.
34 Halliwell B. The role of oxygen radicals in human disease, with particular reference to vascular system. Haemostasis 1993; 23 (Suppl. 01) 118-126.
35 Saigo M, Waters DD, Abe S. et al. Soluble fibrin, C-reactive protein, fibrinogen, factor VII, antithrombin, protein C and S, tissue factor, D-dimer, and prothrombin fragment 1+2 in men with acute myocardial infarction ≤45 years of age. Am J Cardiol 2004; 94: 1410-1413.
36 Molino D, De Santo MG, Marotta R. et al. Plasma levels of plasminogen activator inhibitor type 1, factor VIII, prothrombin activation fragment 1+2, anticardiolipin, and antithrombin antibodies are risk factors for thrombosis in hemodialysis patients. Semin Nephrol 2004; 24: 495-501.